- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| Di | OKYO Pharma Announces Purchase of Shares by Chief Scientific Officer | 206 | GlobeNewswire (Europe) | LONDON and NEW YORK, July 28, 2026 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (Nasdaq: OKYO), a clinical-stage biopharmaceutical company developing investigational therapies for the treatment of neuropathic... ► Artikel lesen | |
| 27.07. | OKYO Pharma to Participate in the BTIG Biotechnology Conference 2026 | 301 | GlobeNewswire (Europe) | LONDON and NEW YORK, July 27, 2026 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (Nasdaq: OKYO), a clinical-stage biopharmaceutical company developing investigational therapies for the treatment of neuropathic... ► Artikel lesen | |
| 27.07. | OKYO Pharma Ltd - 6-K, Report of foreign issuer | 1 | SEC Filings | ||
| OKYO PHARMA Aktie jetzt für 0€ handeln | |||||
| 23.07. | OKYO Pharma Announces Purchase of Shares by Director | 282 | GlobeNewswire (Europe) | LONDON and NEW YORK, July 23, 2026 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (Nasdaq: OKYO), a clinical-stage biopharmaceutical company developing investigational therapies for the treatment of neuropathic... ► Artikel lesen | |
| 23.07. | OKYO Pharma CEO purchases 15,000 shares at $1.54 each | 2 | Investing.com | ||
| 23.07. | OKYO Pharma Announces Purchase of Shares by Chief Executive Officer | 270 | GlobeNewswire (Europe) | LONDON and NEW YORK, July 23, 2026 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (Nasdaq: OKYO), a clinical-stage biopharmaceutical company developing investigational therapies for the treatment of neuropathic... ► Artikel lesen | |
| 22.07. | OKYO Pharma Announces Purchase of Shares by Chairman | 287 | GlobeNewswire (Europe) | LONDON and NEW YORK, July 22, 2026 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (Nasdaq: OKYO), a clinical-stage biopharmaceutical company developing investigational therapies for the treatment of neuropathic... ► Artikel lesen | |
| 22.07. | OKYO Pharma executive purchases 3,500 shares at $1.40 each | 2 | Investing.com | ||
| 22.07. | OKYO Pharma Announces Purchase of Shares by Chief Development Officer and Director | 270 | GlobeNewswire (Europe) | LONDON and NEW YORK, July 22, 2026 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (Nasdaq: OKYO), a clinical-stage biopharmaceutical company developing investigational therapies for the treatment of neuropathic... ► Artikel lesen | |
| 22.07. | OKYO Pharma Announces Purchase of Shares by Chief Medical Officer | 275 | GlobeNewswire (Europe) | LONDON and NEW YORK, July 22, 2026 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (Nasdaq: OKYO), a clinical-stage biopharmaceutical company developing investigational therapies for the treatment of neuropathic... ► Artikel lesen | |
| 21.07. | OKYO Pharma to Present at the H.C. Wainwright 6th Annual Ophthalmology Virtual Conference | 351 | GlobeNewswire (Europe) | LONDON and NEW YORK, July 21, 2026 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (Nasdaq: OKYO), a clinical-stage biopharmaceutical company developing investigational therapies for the treatment of neuropathic... ► Artikel lesen | |
| 21.07. | OKYO Pharma chairman increases stake with share purchase | 2 | Seeking Alpha | ||
| 21.07. | OKYO Pharma Announces Purchase of Shares by Chairman | 322 | GlobeNewswire (Europe) | LONDON and NEW YORK, July 21, 2026 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (Nasdaq: OKYO), a clinical-stage biopharmaceutical company developing investigational therapies for the treatment of neuropathic... ► Artikel lesen | |
| 20.07. | OKYO Pharma Ltd - 6-K, Report of foreign issuer | 1 | SEC Filings | ||
| 20.07. | OKYO Pharma files annual report, raises $25M for phase 3 trial | 2 | Investing.com | ||
| 20.07. | OKYO Pharma Announces Filing of Annual Report with Strengthened Cash Position and Accelerated Phase 3 Plans | 273 | GlobeNewswire (Europe) | LONDON and NEW YORK, July 20, 2026 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (Nasdaq: OKYO), a clinical-stage biopharmaceutical company developing investigational therapies for the treatment of neuropathic... ► Artikel lesen | |
| 20.07. | OKYO Pharma Ltd - 20-F, Annual and transition report of foreign private issuers | 2 | SEC Filings | ||
| 13.07. | H.C. Wainwright cuts OKYO Pharma stock price target to $5 on share count | 3 | Investing.com | ||
| 08.07. | OKYO Pharma Says FDA Supports Advancement Of NEPTUNE Clinical Trial For Urcosimod | 2 | RTTNews | ||
| 08.07. | OKYO Pharma receives FDA feedback on phase 3 neuropathic pain trial | 2 | Investing.com |
1 2 3 4 Weiter >>
64 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| NOVAVAX | 6,410 | +0,94 % | Novavax, Inc.: Novavax Reports First Quarter 2026 Financial Results and Operational Highlights | Total revenue of $140 million in the first quarter of 2026
Pfizer agreement announced in January for non-exclusive license to utilize Matrix-M® in two infectious... ► Artikel lesen | |
| PALATIN TECHNOLOGIES | 7,700 | 0,00 % | Palatin Technologies, Inc.: Palatin to Begin Trading on Nasdaq Stock Exchange | PRINCETON, N.J., May 18, 2026 /PRNewswire/ -- Palatin Technologies, Inc. (NYSE American: PTN), a biopharmaceutical company focused on the discovery and development... ► Artikel lesen | |
| OCUGEN | 1,068 | -1,11 % | Ocugen Announces that the U.S. Food and Drug Administration Has Granted OCU410 Regenerative Medicine Advanced Therapy (RMAT) Designation for Treatment of Geographic Atrophy, Secondary to Dry Age-Related Macular Degeneration | RMAT designation is intended to help expedite development of new regenerative medicines that have potential to treat serious medical conditions with significant unmet needThe designation could accelerate... ► Artikel lesen | |
| NUREXONE BIOLOGIC | 0,269 | +0,75 % | NurExone Biologic Exosomen als möglicher Wendepunkt in der Glaukom-Therapie | ||
| IDEXX LABORATORIES | 485,40 | +0,14 % | IDEXX Laboratories (IDXX) Looks Attractive on Recurring Revenue and High Customer Retention | ||
| PACIFIC BIOSCIENCES OF CALIFORNIA | 1,227 | +1,40 % | Pacific Biosciences of California (PACB) Laps the Stock Market: Here's Why | ||
| REDHILL BIOPHARMA | 0,679 | +6,77 % | RedHill Biopharma Ltd. - 6-K, Report of foreign issuer | ||
| ONCO-INNOVATIONS | 0,415 | +7,52 % | Onco-Innovations Limited: Onco-Innovations Reports Progress Toward a Consistent and Scalable Polymer Manufacturing Process Supporting ONC010 | ||
| NOVOCURE | 12,985 | +0,93 % | NovoCure (NVCR) Upgraded to Buy: What Does It Mean for the Stock? | ||
| OCULAR THERAPEUTIX | 7,200 | +1,41 % | Ocular Therapeutix, Inc.: Ocular Therapeutix Announces Additional Positive Week 52 Data from Landmark SOL-1 Phase 3 Trial of AXPAXLI in Wet AMD | New SOL-1 post-hoc analyses presented at VBS reinforce AXPAXLI's unmatched durability in wet AMD with sustained disease control AXPAXLI demonstrated robust CSFT control with a median time of 39 weeks... ► Artikel lesen | |
| BIOXCEL THERAPEUTICS | 0,710 | +0,85 % | BioXcel Therapeutics Provides Business Update and Reports First Quarter 2026 Financial Results | FDA accepted sNDA for IGALMI® use in at-home (outpatient) setting; set Nov. 14, 2026, as PDUFA date Advancing BXCL501 as a potential acute treatment for agitation associated with Alzheimer's dementia... ► Artikel lesen | |
| ROCKET PHARMACEUTICALS | 2,740 | +1,48 % | Aktien New York: Weitere Verluste - Iran-Krieg und China-News belasten | NEW YORK (dpa-AFX) - Die US-Aktienmärkte haben am Freitag ihre Talfahrt fortgesetzt. Der anhaltende Iran-Krieg und die weiter steigenden Ölpreise mahnen die Anleger zur Vorsicht. Auf die Stimmung drückte... ► Artikel lesen | |
| VOYAGER THERAPEUTICS | 2,680 | +2,13 % | Voyager Therapeutics, Inc.: Voyager Demonstrates Single IV Dose of VY1706 Well Tolerated, Reduced Tau in 6-Month GLP Toxicology Study; Initiation of Clinical Trial in Alzheimer's Disease Expected H2 2026 | - Data presented as Developing Topics poster at AAIC 2026 - LEXINGTON, Mass., July 13, 2026 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (Nasdaq: VYGR), a biotechnology company dedicated to leveraging... ► Artikel lesen | |
| PALISADE BIO | 1,895 | 0,00 % | Palisade Bio, Inc.: Palisade Bio Receives FDA Clearance of IND for PALI-2108 and Plans to Initiate Global Phase 2 ASCENTRA-UC Study in Ulcerative Colitis | ASCENTRA-UC expected to enroll up to 204 patients with moderately to severely active ulcerative colitis across North America and Europe First patient enrollment anticipated in the second half of 2026... ► Artikel lesen | |
| ADAPTIMMUNE THERAPEUTICS | 0,162 | 0,00 % | Merck And ADAP Crisis Task Force Reach Agreement To Expand IDVYNSO Access |
OKYO PHARMA LIMITED gehört der Branche Biotechnologie an. Der aktuelle Kurs liegt bei 1,680 Euro und damit 0,00 % im Plus.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu OKYO PHARMA LIMITED finden Sie auf Wallstreet Online.